Latest News

May 26, 2010

Health Enhancement Products Announces Details of Its June 8th Scientific Panel Presentation

May 11, 2010

Health Enhancement Products Schedules Press Event June 8 to Present Breakthroughs in Its Cholesterol Management Research

April 26, 2010

Health Enhancement Products Secures Funding Enabling the Company to Begin Phase O Clinical Trials

April 21, 2010

Health Enhancement Products Names Denis M. Callewaert, Ph.D. to Its New Chief Science Officer Position

April 13, 2010

Professor of Molecular Toxicology at Penn State University, Jack Vanden Heuvel PhD, to Join Health Enhancement Products Scientific Advisory Boardt

March 9, 2010

Wayne State University Researchers Discover Potentially New Means to Regulate Bad Cholesterol and Raise HDL (Good Cholesterol) With Bioactive Molecules Derived From ProAlgaZyme(TM) -- a Proprietary Algal Extract

July 20, 2010

Health Enhancement Products Expands Scientific Advisory Board Dr. Donald Armstrong, Noted Expert in Oxidative Stress and Inflammation, Joins as Science Advisor

 


Health Enhancement Products is a member of these organizations







 
Health Enhancement Products names Peter Vitulli as interim CEO

Press Release Source: Health Enhancement Products, Inc
On Tuesday September 8, 2009, 8:00 am EDT

 

SCOTTSDALE, AZ, Sept. 8 /PRNewswire-FirstCall/ - Health Enhancement Products, Inc. (HEPI-OTCBB) announced the appointment of Peter Vitulli, a seasoned corporate veteran with a combination of Fortune 500 corporate experience and small/medium growth company expertise, as interim CEO.

Mr. Vitulli's vast experience includes his current position as Chairman of Efficas, Inc., a venture backed leading developer and marketer of natural bioactive compounds utilized for nutritional management of health and wellness in humans and animals. The Efficas scientific platform and expertise focus on the immune system and the tools required in identifying, investigating and assessing effects of bioactives on immune function. Mr. Vitulli spent the first 16 years of his career at the Quaker Oats Company, most recently as President of the North American Gatorade business, one of the premier functional food products in the world.

Mr. Vitulli stated: "I believe Health Enhancement's Products' ProAlgaZyme(TM) represents a break-through technology which will have several health and wellness applications. My goal is to help the team continue its rigorous scientific study while simultaneously developing the business strategy to successfully position ProAlgaZyme as a safe and effective way to address multiple chronic conditions."

To view Mr. Vitulli's complete resume go to: http://www.heponline.com/PVitulliCV-May2009PDF.pdf

John Gorman, Director of Sales for HEPI stated: "Our company is currently undergoing the most extensive clinical trials and scientific studies in its history, which thus far are once again confirming the efficacy of ProAlgaZyme (PAZ). We need a CEO capable of understanding these results and having the expertise to bring PAZ to market and to properly prepare us for introduction to the functional food and pharmaceutical industries. Mr. Vitulli, with vast experience in both biotech research and product marketing, is the person that can take us to that next level."

About Health Enhancement Products, Inc.

Health Enhancement Products, Inc. is an innovative health and wellness company engaged in the development of dietary supplements, food additives and ingredients using only pure, all-natural compounds. The Company's premier product is ProAlgaZyme (PAZ), a liquid product drawn from living algae grown in purified water. The water in which the algae is grown is drawn off, filtered and bottled as ProAlgaZyme.

Safe Harbor Statement

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.

 

<< Back to Releases

 

© 2009 HEALTH ENHANCEMENT PRODUCTS INC.
            PRIVACY POLICY           DISCLAIMER